Live Breaking News & Updates on Global Health At Weill Cornell Medicine

Stay updated with breaking news from Global health at weill cornell medicine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Improving care of hospitalized patients with HIV in Tanzania

Researchers at Weill Cornell Medicine have shown that three months of social worker follow-up support to people hospitalized with HIV in Tanzania had health benefits at low cost. ....

Robertn Peck , Sean Murphy , Blood Institute , National Heart , Weill Bugando School Of Medicine , Global Health At Weill Cornell Medicine , Fogarty International Center , Lisa Rosen Metsch At Columbia University , Weill Cornell Medicine , Weill Cornell , Saharan Africa , Weill Bugando School , Mwanza Interventions Trial Unit , Lisa Rosen Metsch , Columbia University , Saidi Kapiga , Mwanza Intervention Trials , Global Health , National Institute , Mental Health , National Institutes ,

Improving care of hospitalized patients with HIV in Tanzania

Improving care of hospitalized patients with HIV in Tanzania
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Sean Murphy , Robert Peck , Robertn Peck , Lisa Rosen Metsch At Columbia University , Weill Bugando School Of Medicine , Global Health At Weill Cornell Medicine , Weill Cornell Medicine , Weill Cornell , Saharan Africa , Weill Bugando School , Mwanza Interventions Trial Unit , Lisa Rosen Metsch , Columbia University , Saidi Kapiga , Mwanza Intervention Trials , Global Health , Linkage Case Management , Posthospitalization Outcomes , People With , Linkage To Care Intervention , Hospitalized People With ,

Drug-resistant TB responds rapidly to bedaquiline-based therapy

Patients who have drug-resistant tuberculosis have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine. ....

Myung Hee Lee , Danielw Fitzgerald , Kayvan Zainabadi , Drug Administration , Global Health At Weill Cornell Medicine , World Health Organization , Haitian Study Group On Opportunistic Infections , National Institute Of Allergy , National Institutes Of Health , Weill Cornell Medicine , Infectious Diseases , Weill Cornell , Global Health , Haitian Study Group , Opportunistic Infections , Tropical Medicine , Scientific Reports , National Institute , National Institutes ,

Second-line treatment for drug-resistant tuberculosis is as effective as first-line medicines

Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO Centers in Haiti. ....

United States , New York , Danielw Fitzgerald , Kayvan Zainabadi , Myung Hee Lee , Global Health At Weill Cornell Medicine , Drug Administration , World Health Organization , Haitian Study Group On Opportunistic Infections , Weill Cornell Medicine , Infectious Diseases , Weill Cornell , Global Health , United States Food , Haitian Study Group , Opportunistic Infections , Tropical Medicine , Scientific Reports , Drug Resistant Tuberculosis , Infectious Diseases ,

Drug-resistant tuberculosis responds rapidly

<p>Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO Centers in Haiti. Second-line medications are those that are given when one or more of the drugs given first for the disease are not effective. The research could have implications for shortening the duration of treatment for drug-resistant TB, which currently requires medications for up to 2 years, while those with drug-sensitive TB complete treatment in about 6 months. </p>
....

United States , New York , Myung Hee Lee , Danielw Fitzgerald , Kayvan Zainabadi , World Health Organization , Drug Administration , Global Health At Weill Cornell Medicine , Haitian Study Group On Opportunistic Infections , Weill Cornell Medicine , Infectious Diseases , Weill Cornell , Global Health , World Health , United States Food , Haitian Study Group , Opportunistic Infections , Tropical Medicine , Scientific Reports ,